The Permeability Transition in Hepatic Encephalopathy
The Permeability Transition in Hepatic Encephalopathy
批准号:
6953706
负责人:
MICHAEL David NORENBERG
金额:
$14.49万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-01 至 2008-07-31
中文摘要
描述(由申请人提供):肝性脑病(HE)是严重肝功能衰竭患者发病率和死亡率的重要原因。急性肝性脑病合并暴发性肝衰竭预后极差,目前尚无特效治疗方法,除非进行紧急肝移植。尽管其发病机制尚不清楚,但氨被认为是一种神经毒素,而星形胶质细胞似乎是氨神经毒性的主要靶点。此外,生物能量学和氧化应激的改变被认为在这种疾病中发挥了重要作用。这些事实促使人们考虑将线粒体通透性转变(MPT)作为HE和氨神经毒性发病机制中的一个因素。MPT是一个钙依赖、环孢素A(CsA)敏感的过程,由于线粒体膜内孔的打开导致离子梯度的崩溃,最终导致线粒体功能障碍。我们最近发现氨在培养的星形胶质细胞中诱导了MPT。我们打算使用氨处理的神经细胞培养和HE/高氨血症(HA)的活体模型来研究MPT在HE和高氨血症中的作用。我们的工作假设是氨诱导星形胶质细胞中的MPT,最终导致线粒体衰竭和星形胶质细胞功能障碍。这一概念的一个推论是,抑制或干预星形胶质细胞中MPT的发育可能会改善HE的中枢神经系统功能障碍。本提案的具体目的是:1)确定氨诱导培养的神经细胞MPT的相关因素。我们的重点将集中在与HE/H的发病机制有关的药物上,这些药物也已被证明在其他细胞中诱导MPT。具体地说,我们将研究钙、活性氧、一氧化氮、pH和谷氨酰胺的作用。我们将确定这些因子在氨处理的培养物中是否升高,以及减少它们的生产或阻止它们的作用是否降低或废除MPT。此外,我们还将研究这些因素之间可能存在的顺序相互关系。2)为了确定氨诱导的星形胶质细胞异常(形态改变、神经递质摄取缺陷和细胞肿胀)是否由MPT介导,我们将研究MPT的抑制剂(环孢素A、bongkrekik酸)是否能够减轻或阻断氨的有害影响。3)探讨线粒体功能障碍在MPT介导的细胞损伤中的作用。我们将确定氨处理后线粒体的功能状态,然后探讨改善能量代谢是否会抑制氨诱导的细胞损伤。4)探讨硫代乙酰胺治疗(HE)和高氨血症模型中是否存在MPT。我们还将确定在体外抑制MPT的因素(如环孢素A、三氟拉嗪)是否也能在体内做到这一点。此外,我们将评估MPT阻滞剂改善临床、组织病理学、神经化学异常和HE/HA中观察到的脑肿胀程度的能力。我们相信,这些研究将产生与HE发病机制有关的关键数据,并可能有助于开发治疗这种疾病的新治疗策略。
英文摘要
DESCRIPTION (provided by applicant): Hepatic encephalopathy (HE) is an important cause of morbidity and mortality in patients with severe liver failure. Acute HE associated with fulminant hepatic failure has an extremely poor prognosis and specific therapy is not available, short of an emergency liver transplantation. Although its pathogenesis remains poorly understood, ammonia is strongly implicated as a neurotoxin, and astrocytes appear to be the primary target of ammonia neurotoxicity. Additionally, altered bioenergetics and oxidative stress are thought to play a major role in this disorder. These facts led to a consideration of the involvement of mitochondrial permeability transition (MPT) as a factor in the pathogenesis of HE and ammonia neurotoxicity. The MPT is a Ca2+-dependent, cyclosporin A (CsA)-sensitive process due to the opening of a pore in the inner mitochondrial membrane leading to a collapse of ionic gradients and ultimately to mitochondrial dysfunction. We have recently shown that ammonia induced the MPT in cultured astrocytes. We intend to examine the role of the MPT in HE and hyperammonemia using ammonia-treated neural cell cultures and in vivo models of HE/hyperammonemia (HA). Our working hypothesis is that ammonia induces the MPT in astrocytes, culminating in mitochondrial failure and astroglial dysfunction. A corollary of this concept is that inhibition or interference in the development of the MPT in astrocytes may ameliorate CNS dysfunction in HE. The Specific Aims of this proposal are: 1) To identify the factors responsible for the ammonia-induced MPT in cultured neural cells. Our focus will be on agents implicated in the pathogenesis of HE/H that have also been shown to induce the MPT in other cells. Specifically, we will examine the role of Ca 2+, reactive oxygen species, nitric oxide, pH and glutamine. We will determine whether these factors are elevated in ammonia-treated cultures, and whether diminishing their production or blocking their actions reduces or abolishes the MPT. Additionally, we will examine possible sequential interrelationships among these factors. 2) To determine whether ammonia-induced abnormalities in astrocytes (morphological alterations, defects in neurotransmitter uptake, and cell swelling) are mediated by the MPT, we will investigate whether inhibitors of the MPT (CsA, bongkrekik acid) are capable of diminishing or blocking the deleterious effects of ammonia. 3) To investigate the involvement of mitochondrial dysfunction as a potential factor in MPT-mediated cell injury. We will determine the state of mitochondrial function after ammonia treatment, and then investigate whether improving energy metabolism will inhibit ammonia-induced cellular injury. 4) To clarify whether the MPT occurs in in vivo models of HE (thioacetarnide treatment) and hyperammonemia. We will also determine whether factors that inhibit the MPT in vitro (e.g., CsA, trifluoperazine) are also capable of doing so in vivo. Additionally, we will assess the ability of MPT blockers to improve the clinical, histopathologic, neurochemical abnormalities, and the extent of brain swelling observed in HE/HA. We believe that these studies will yield critical data bearing on the pathogenesis of HE, and may potentially aid in the development of novel therapeutic strategies for the treatment of this condition.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Astrocyte swelling/Brain Edema in Acute Liver Failure: Role of Endothelial Cells
-
批准号:8443315
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Trauma-Induced Astrocyte Swelling/Brain Edema: Role of NKCC
-
批准号:8259058
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Trauma-Induced Astrocyte Swelling/Brain Edema: Role of NKCC
-
批准号:8195584
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Trauma-Induced Astrocyte Swelling/Brain Edema: Role of NKCC
-
批准号:8394618
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Trauma-Induced Astrocyte Swelling/Brain Edema: Role of NKCC
-
批准号:7930026
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:MICHAEL David NORENBERG
-
依托单位:
The Permeability Transition in Hepatic Encephalopathy
-
批准号:6681641
-
项目类别:
-
资助金额:$14.49万
-
财政年份:2003
-
负责人:MICHAEL David NORENBERG
-
依托单位:
The Permeability Transition in Hepatic Encephalopathy
-
批准号:6798324
-
项目类别:
-
资助金额:$14.49万
-
财政年份:2003
-
负责人:MICHAEL David NORENBERG
-
依托单位:
NFkB in the Astrocyte Swelling/Brain Edema with Acute Liver Failure
-
批准号:8134013
-
项目类别:
-
资助金额:$27.13万
-
财政年份:2003
-
负责人:MICHAEL David NORENBERG
-
依托单位:
NFkB in the Astrocyte Swelling/Brain Edema with Acute Liver Failure
-
批准号:8323574
-
项目类别:
-
资助金额:$27.13万
-
财政年份:2003
-
负责人:MICHAEL David NORENBERG
-
依托单位:
The Permeability Transition in Hepatic Encephalopathy
-
批准号:7123928
-
项目类别:
-
资助金额:$27.07万
-
财政年份:2003
-
负责人:MICHAEL David NORENBERG
-
依托单位:
NFkB in the Astrocyte Swelling/Brain Edema with Acute Liver Failure
-
批准号:7889164
-
项目类别:
-
资助金额:$27.28万
-
财政年份:2003
-
负责人:MICHAEL David NORENBERG
-
依托单位:
The Permeability Transition in Hepatic Encephalopathy
-
批准号:7284854
-
项目类别:
-
资助金额:$26.28万
-
财政年份:2003
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Cellular and molecular responses in human spinal cord injury
-
批准号:6609158
-
项目类别:
-
资助金额:$5.36万
-
财政年份:2002
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Cellular and molecular responses in human spinal cord injury
-
批准号:6604775
-
项目类别:
-
资助金额:$5.36万
-
财政年份:2002
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Cellular and molecular responses in human spinal cord injury
-
批准号:6612404
-
项目类别:
-
资助金额:$5.36万
-
财政年份:2002
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Cellular and molecular responses in human spinal cord injury
-
批准号:6478904
-
项目类别:
-
资助金额:$5.36万
-
财政年份:2001
-
负责人:MICHAEL David NORENBERG
-
依托单位:
Cellular and molecular responses in human spinal cord injury
-
批准号:6333136
-
项目类别:
-
资助金额:$5.36万
-
财政年份:2000
-
负责人:MICHAEL David NORENBERG
-
依托单位:
HEPATIC COMA--GLIAL BENZODIAZEPINE RECEPTORS & STEROIDS
-
批准号:2460641
-
项目类别:
-
资助金额:$16.68万
-
财政年份:1996
-
负责人:MICHAEL David NORENBERG
-
依托单位:
HEPATIC COMA--GLIAL BENZODIAZEPINE RECEPTORS & STEROIDS
-
批准号:2447003
-
项目类别:
-
资助金额:$3.06万
-
财政年份:1996
-
负责人:MICHAEL David NORENBERG
-
依托单位:
HEPATIC COMA--GLIAL BENZODIAZEPINE RECEPTORS & STEROIDS
-
批准号:2274284
-
项目类别:
-
资助金额:$14.59万
-
财政年份:1996
-
负责人:MICHAEL David NORENBERG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
SOD1介导星形胶质细胞活化调控hNSC移植细胞存活的机制研究
-
批准号:82372136
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:付雪梅
-
依托单位:
TXNIP调控实验性青光眼视乳头星形胶质细胞的激活及其机制研究
-
批准号:82371048
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:钟一声
-
依托单位:
Ascl1介导Wnt/beta-catenin通路在TLE海马硬化中反应性Astrocytes异常增生的作用及调控机制
-
批准号:31760279
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2017
-
负责人:丁银秀
-
依托单位:
趋化因子RANTES激活神经胶质细胞的信号转导网络研究
-
批准号:30470376
-
项目类别:面上项目
-
资助金额:22.0万元
-
批准年份:2004
-
负责人:张业
-
依托单位: